Access the full text.
Sign up today, get DeepDyve free for 14 days.
(1995)
Projected yield of screening blood donors for HIV , HBV and HCV nucleic acids ( abstract )
(1995)
Infectious disease testing for blood transfusions.Oncology, 9 11
(1995)
Will human immunodeficiency virus p 24 antigen screening increase the safety of the blood supply and , if so , at what cost ? ( editorial )
J. Rasenack, H. Schlayer, F. Hettler, T. Peters, S. Preisler‐Adams, W. Gerok (1995)
Hepatitis B virus infection without immunological markers after open-heart surgeryThe Lancet, 345
M. Busch, E. Operskalski, J. Mosley, C. Stevens, E. Schiff, S. Kleinman, H. Lee, M. Lee, M. Harris (1994)
Epidemiologic background and long‐term course of disease in human immunodeficiency virus type 1‐infected blood donors identified before routine laboratory screening. Transfusion Safety Study GroupTransfusion, 34
(1995)
Applications of molecular biology to infectious disease screening of blood donors
Scientist 11, Jerome H. Holland Laboratory, American Red Cross; and Scientific Director
Cost - effectiveness of expanded HIV test protocols for donated blood ( abstract )
M. Gerber, K. Krawczyński, M. Alter, R. Sampliner, H. Margolis (1992)
Histopathology of community acquired chronic hepatitis C. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 5 5
M. Busch (1994)
HIV AND BLOOD TRANSFUSIONS: FOCUS ON SEROCONVERSIONVox Sanguinis, 67
(1994)
Detection of HIV-I by RNA PCR in factor VIU concentrates (letter)
H. Alter (1995)
To C or not to C: these are the questions.Blood, 85 7
J. Bukh, P. Wantzin, K. Krogsgaard, F. Knudsen, R. Purcell, Roger Miller (1993)
High Prevalence of Hepatitis C Virus (HCV) RNA in Dialysis Patients: Failure of Commercially Available Antibody Tests to Identify a Significant Number of Patients with HCV InfectionThe Journal of Infectious Diseases, 168
(1995)
Failure of 2 nd - and 3 rd - generation HCV ELlSA and RIBA to detect HCV polymerase chain reaction - positive donations ( letter )
Residual risk of transfusion - associated HIV transmission ( abstract )
Jagodzinski Jagodzinski, Kraus Kraus, Garrett Garrett (1994)
Detection of hepatitis B viral sequences in early HBV infection (abstract)Transfusion, 34
Time course and kinetics of HIV viremia during primary infection ( abstract )
M. Chudy, H. Bornhak, J. Löwer (1997)
Detection of hepatitis B viral sequences in early HBV infectionJournal of Microbiological Methods, 30
M. Alter, H. Margolis, K. Krawczyński, F. Judson, A. Mares, W. Alexander, Pindiga Hu, Joan Miller, M. Gerber, R. Sampliner, Emory Meeks, M. Beach (1992)
The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.The New England journal of medicine, 327 27
F. Pont, D. Costagliola, C. Rouzioux, A. Valleron (1995)
How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests?Transfusion, 35
San Francisco; and Vice President
PhD, Senior Study Director
L. Petersen, Glen Satten, R. Dodd, M. Busch, Steve Kleinman, A. Grindon, B. Lenes (1994)
Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibodyTransfusion, 34
(1995)
Risk behaviors and test seeking among HIV - positive blood donors ( abstract )
M. Busch, L. Lee, G. Satten, D. Henrard, H. Farzadegan, K. Nelson, S. Read, R. Dodd, L. Petersen (1995)
Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donorsTransfusion, 35
Human immunodeficiency virus type I - infected blood donors : behavioral characteristics and reasons for donation . HIV Blood Donor Study Group
Demographic and serologic characteristics of volunteer blood donors : the Retrovirus Epidemiology Donor Study ( REDS )
(1995)
Characterization of active blood donors who recently donated blood primarily to receive an HIV test ( abstract )
Williams Williams, Thomson Thomson, Horton Horton, Kleinman Kleinman (1995)
For the NHLBI REDS Study. Characterization of active blood donors who recently donated blood primarily to receive an HIV test (abstract)Transfusion, 35
Background: There currently is debate on whether to include new assays for viral antigens and nucleic acids in the battery of screening tests applied to all blood donations. Proposals call for implementation of p24 antigen screening tests to help identify donors who are infected with human immunodeficiency virus type 1 (HIV‐1) but have not yet seroconverted (window‐period donors). There is concern, however, that people at higher risk for HIV infection will be attracted to blood centers in order to obtain the results of an HIV assay that is not routinely available elsewhere. Therefore, the benefit of antigen testing may be offset by an increase in the HIV incidence rate among blood donors. Study Design and Methods: Estimates were obtained from previous reports for the HIV incidence rate among blood donors, the percentage of donations from test‐seeking donors, the duration of the HIV‐infectious window period, and the performance of p24 antigen screening assays. Sensitivity analyses were performed by using various percentages of test‐seeking donors following implementation of antigen testing and various HIV incidence rate ratios of test‐seekers to nonseekers. Hypothetical residual HIV risks were calculated for multiple scenarios and compared to the current estimate of HIV risk without antigen screening of blood donations. Results: If antigen testing reduces the window period by 27 percent (e.g., from 22 days to 16 days), and the HIV incidence rate among test‐seekers is 30 times that among nonseekers, then the benefit of antigen testing will be eliminated if the percentage of test‐seekers (currently estimated at 3.2%) increases to 5.7 percent. If antigen testing reduces the window period by approximately 45 percent (e.g., from 22 days to 10 days or from 13 days to 6 days) and the HIV incidence rate ratio (test‐seekers vs. nonseekers) is assumed to be equal to the HIV prevalence ratio (5.3), then the percentage of donations from test‐seeking donors would have to increase to 25 percent of all donations to offset the benefit of antigen screening. Conclusion: This model helps identify the key measures for assessing the potential adverse effect of increased test seeking as a consequence of the addition of p24 antigen (or other direct virus) assays to blood donor screening programs. In most scenarios, the beneficial effect of antigen screening exceeded the potential detrimental effect of attracting higher‐risk, test‐seeking donors. The possibility cannot be ruled out, however, that a subgroup of high‐risk, test‐seeking donors attracted to the blood centers by a new HIV test will offset the reduction in the residual risk of HIV infection associated with antigen screening.
Transfusion – Wiley
Published: Mar 1, 1996
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.